Vassilios Dimitropoulos, MD
Dermatology · Michigan City, INNPI 1194838045
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.7%), food and beverage and education — rather than concentrated in one kind of arrangement. UCB GmbH accounts for 82.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $1,275 and has fallen 97.4% since, to $34 in 2025. That places this record below the midpoint for dermatology clinicians in IN, where the typical reported total is $3,818.
Across 21 payments — averaging $73.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB GmbH$1K
- AbbVie$186
- Merz North America, Inc.$31
- Pfizer$27
- Strata Skin Sciences, Inc.$25
Across 203 payments — averaging $8801.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.3M
- AbbVie$331K
- Regeneron$102K
- Galderma Research & Development, LLC$26K
- UCB SA$11K
- Dermira, Inc.$9K
- plus $6K from 1 others
What the payments were for
- Travel & lodging$76150%
- Food & beverage$75649%
- Education$151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB GmbH | 11 | $1,264 |
| AbbVie | 5 | $186 |
| Merz North America, Inc. | 1 | $31 |
| Pfizer | 2 | $27 |
| Strata Skin Sciences, Inc. | 2 | $25 |
How this compares
$1,533 in reported general payments places this provider in the 35th percentile of 202 dermatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 150 | $11,668 |
| Triamcinolone Acetonide | 112 | $1,666 |
| Ketoconazole | 78 | $1,069 |
| Metronidazole | 15 | $936 |
| Tretinoin | 11 | $839 |
| Clindamycin Phosphate | 21 | $758 |
| Mometasone Furoate | 39 | $675 |
| Halobetasol Propionate | 11 | $530 |
| Econazole Nitrate | 18 | $465 |
| Doxycycline Hyclate | 13 | $344 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $288 |
| Mupirocin | 32 | $188 |
| Hydrocortisone | 22 | $187 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 23 | $146 |
| Ciprofloxacin Hcl | 13 | $77 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Michigan City
- Scott GuenthnerPlainfield$1.6M
- David RosmarinIndianapolis$1.1M
- Christopher ObeimeIndianapolis$907K
- Scott FretzinIndianapolis$794K
- Priya YoungIndianapolis$492K
- Jeffrey SassmannshausenFort Wayne$489K
- Nikolajs PerdueIndianapolis$302K
- Michael SheehanColumbus$297K
- Alfred KnableNew Albany$203K
- Megan LandisCorydon$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.